About US
Contact us
-
Pfizer's Xeljanz matches immunosuppressant combo in rheumatoid arthritis studyPfizer’s troubled JAK inhibitor Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s higher dose in rheumatoid arthritis. Now, Pfizer is hoping for better results u2019/6/14
-
Teva recall: Tainted blood pressure drugs continue to show up in U.S. supplyDespite the FDA’s repeated efforts to clear the U.S. drug supply of hypertension drugs tainted with impurities believed to cause cancer, they keep being discovered. The most recent recall is 10 lots2019/6/14
-
Merck helps FDA test blockchain for track and traceThere has been a lot of talk about how blockchain computer technology can better protect the U.S. drug supply chain. Merck & Co. intends to test that theory. The U.S. drugmaker has beeninvited by2019/6/13
-
FDA: Eli Lilly touts Olumiant safety data for unapproved high doseThe path to success for Eli Lilly and Incyte’s rheumatoid arthritis med Olumiant in the U.S. has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Could new long-term sa2019/6/13
-
ADA 2019 goes beyond diabetes as 'holistic' care comes into focusSAN FRANCISCO—If you’d popped into just a few sessions at the American Diabetes Association annual meeting, you easilycould have thought you’d wandered into a cardiovascular meeting, a kidney disease2019/6/12
-
Judge holds up Teva's $85M opioid settlement, sinking shares back to pre-2000 levelsTeva made headlines late last month when it inked an $85 million settlement with Oklahoma prosecutorsover opioid mismarketing allegations—even after CEOKåre Schultz said the company wouldn't strike2019/6/12
-
It's Catalyst vs. the feds as tiny drugmaker sues FDA over 'capricious' approval for rivalFor a relatively unknown drugmaker, Catalyst Pharmaceuticals has made plenty of headlines since it won approval for its rare disease drug Firdapse. And isn’t shying away from more controversy.2019/6/11
-
Accidental court filing reveals Novartis' kickback settlement talks: reportAfter six years of legal wrangling and unflattering headlines, Novartis appears close to putting a doctor kickback lawsuit behind it—and the revelation came from a court filing that was supposed to b2019/6/11
-
Roche touts phase 2 Gazyva data in lupus patients with a potentially fatal kidney complicationOne brand-new FDA approval and one trial win for its blood cancer drug Gazyva added up to a double dose of good news for Roche Monday. The Swiss drugmaker snapped up a comboapproval for lympho2019/6/10
-
Merck's Keytruda, passing Opdivo, bags double head and neck cancer OKTuesday was a twofer for Merck & Co., which notched two new FDA approvals for blockbuster Keytruda in previously untreated head and neck cancer patients. Regulatorsgreen-lightedthe immuno-oncolog2019/6/10